Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapyFirst Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLCRevolution Medicines’ third RAS(ON) inhibitor to receive this designation REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zoldonrasib, a RAS(ON) G12D-selective inhibitor, for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have been previously treated with anti-PD-1/PD-L1 therapy and
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (NASDAQ:RVMD) was given a new $143.00 price target on by analysts at Mizuho.MarketBeat
- JPM 26: Day 1 – drug prices and policy changes drive the agenda [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines declines to comment on M&A speculation at conference [Seeking Alpha]Seeking Alpha
- JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax [Yahoo! Finance]Yahoo! Finance
- AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/7/26 - Form 144
- RVMD's page on the SEC website